Fig. 4

The survival curve comparing patients with APOBEC2-positive(red) and APOBEC2-negative(blue): (a) Overall survival (OS) curve of patients in overall cohort(n = 496); (b) OS curve of patients receiving postoperative chemotherapy (n = 339); (c) OS curve of patients larger than the median age and receiving postoperative chemotherapy (n = 160); (d) OS curve of stage III patients who received postoperative chemotherapy (n = 171); (e) Disease-free survival (DFS) curve of patients in overall cohort(n = 496); (f) DFS curve of patients receiving postoperative chemotherapy (n = 339); (g) DFS curve of patients larger than the median age and receiving postoperative chemotherapy (n = 160); (h) DFS curve of stage III patients who received postoperative chemotherapy (n = 171)